Clinical Trials · NCT06439277
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 300
- Start date
- Jun 2024
- Locations
- 73 sites, 12 countries
- Primary endpoint
- Percent Change from Baseline in Body Mass Index (BMI)